Tenax Therapeutics, Inc. earnings per share and revenue
On Mar 10, 2026, TENX reported earnings of -0.38 USD per share (EPS) for Q4 25, beating the estimate of -0.42 USD, resulting in a 10.23% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +31.67% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.40 USD, with revenue projected to reach -- USD, implying an increase of 5.26% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-
Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Tenax Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Tenax Therapeutics, Inc. reported EPS of -$0.38, beating estimates by 10.23%, and revenue of $0.00, 0% as expectations.
How did the market react to Tenax Therapeutics, Inc.'s Q4 2025 earnings?
The stock price moved up 31.67%, changed from $11.02 before the earnings release to $14.51 the day after.
When is Tenax Therapeutics, Inc. expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Tenax Therapeutics, Inc.'s next earnings report?
Based on 4
analysts, Tenax Therapeutics, Inc. is expected to report EPS of -$0.40 and revenue of -- for Q1 2026.